Mirati Marks Another Milestone With Adagrasib

US FDA Grants Breakthrough Designation

 
• By Alaric DeArment

Mirati executives are still being pushed to defend the safety profile for the KRAS G12C inhibitor adagrasib, which has been seen as a potential disadvantage relative to Amgen’s Lumakras.

Neon Light Sign Lungs Icon
Mirati received a breakthrough therapy designation from the FDA for KRAS G12C inhibitor adagrasib • Source: Shutterstock

More from Strategy

More from Business